Japan Humira Market Size, Share, and COVID-19 Impact Analysis, By Product (Branded and Biosimilar), By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn’s Disease, and Others), and Japan Humira Market Insights, Industry Trend, Forecasts to 2035

Japan Humira Market Insights Forecasts to 2035  

• The Japan Humira Market Size was Estimated at USD 88.5 Billion in 2024
• The Market Size is Expected to Decline at a CAGR of Around -7.97% from 2025 to 2035
• The Japan Humira Market Size is Expected to Reach USD 35.5 Billion by 2035

According to a research report published by Spherical Insights & Consulting, The Japan Humira Market Size is anticipated to reach USD 35.5 Billion by 2035, Declining at a CAGR of -7.97% from 2025 to 2035. The Japan humira market is driven by various factors, including the high prevalence of autoimmune diseases, the rise in the ageing population, continuous investment in R&D, patients' preferences for newer therapies, and government support for advanced therapies.

Market Overview

Humira is also recognized as adalimumab. Humira is a biological therapy and a monoclonal antibody that targets tumour necrosis factor alpha. A protein that is involved in inflammatory responses.  This market focuses on the development, sale, and usage of humira. It is used to treat rheumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis, and ulcerative colitis. Humira is available in branded and biosimilar forms. Humira has revolutionized the treatment of autoimmune diseases like rheumatoid arthritis, psoriasis, and Crohn's disease. The increasing incidence of autoimmune conditions, such as psoriatic arthritis, plaque psoriasis, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, and Crohn's disease, is expected to boost the growth rate of the market. The is one of the largest aging population country, which further drive the demand for humira. The advancement in telemedicine and digital tools presents a new opportunity for patient engagement and management.

Report Coverage

This research report categorizes the market for the Japan humira market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan humira market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan humira market.

Driving Factors

The rising cases of psoriatic arthritis, plaque psoriasis, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, and Crohn's disease are one of the primary driving factors for this market. Japan has the largest aging population, and the aging population is more susceptible to chronic disease, which creates demand for biologics. The increased support from the government through investments further drives the market growth. Additionally, technological advancements and a rise in R&D positively contribute to the market expansion.

Restraining Factors

The rising competition from the alternative biologics limits the market growth. Humira is one of the expensive biologic drugs, limiting accessibility to price-sensitive patients. Additionally, humira has several side effects that further limit the market expansion.

Market Segmentation

The Japan humira market share is classified into product and application.    

• The branded segment held the dominant share in 2024 and is expected to grow at a significant CAGR during the forecast period.       

The Japan humira market is segmented by product into branded and biosimilar. Among these, the branded segment held the dominant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This segmental growth is attributed to its strong brand recognition, proven efficacy, and long-standing presence. Additionally, they used across multiple therapeutic areas.

• The rheumatoid arthritis segment accounted for a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period.     

The Japan humira market is segmented by application into rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and others. Among these, the rheumatoid arthritis segment accounted for a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. This is due to the rising prevalence of RA. Additionally, there is a growing need for early diagnosis and treatment access.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan humira market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
• AbbVie GK
• Eisai Co., Ltd.
• Biocon Biologics
• Sandoz
• Other

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan humira market based on the below-mentioned segments:

Japan Humira Market, By Product

• Branded
• Biosimilar

Japan  Humira Market, By Application

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Crohn’s Disease
• Others